Francisco Díaz‐Mitoma

4.8k total citations
138 papers, 3.4k citations indexed

About

Francisco Díaz‐Mitoma is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, Francisco Díaz‐Mitoma has authored 138 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Epidemiology, 45 papers in Immunology and 25 papers in Infectious Diseases. Recurrent topics in Francisco Díaz‐Mitoma's work include Immunotherapy and Immune Responses (25 papers), Hepatitis B Virus Studies (24 papers) and Herpesvirus Infections and Treatments (21 papers). Francisco Díaz‐Mitoma is often cited by papers focused on Immunotherapy and Immune Responses (25 papers), Hepatitis B Virus Studies (24 papers) and Herpesvirus Infections and Treatments (21 papers). Francisco Díaz‐Mitoma collaborates with scholars based in Canada, United States and France. Francisco Díaz‐Mitoma's co-authors include Ashok Kumar, Ali Azizi, Marko Kryworuchko, L G Filion, Katrina Gee, W. David Creery, Wilfred Lim, Maya Kozlowski, Susan Aucoin and D. William Cameron and has published in prestigious journals such as The Lancet, JAMA and Journal of Biological Chemistry.

In The Last Decade

Francisco Díaz‐Mitoma

136 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francisco Díaz‐Mitoma Canada 32 1.4k 1.1k 697 584 447 138 3.4k
Lígia A. Pinto United States 37 2.3k 1.7× 2.0k 1.8× 530 0.8× 825 1.4× 782 1.7× 152 5.1k
Mutsunori Shirai Japan 34 774 0.6× 1.1k 1.0× 277 0.4× 956 1.6× 257 0.6× 96 3.6k
Jian Yan United States 36 1.1k 0.8× 1.7k 1.6× 512 0.7× 1.1k 1.9× 460 1.0× 132 3.5k
Alan Heath United Kingdom 33 1.6k 1.2× 304 0.3× 994 1.4× 433 0.7× 358 0.8× 123 3.4k
Alistair J. Ramsay Australia 37 1.3k 0.9× 3.4k 3.1× 850 1.2× 992 1.7× 620 1.4× 81 6.3k
Didier Hober France 38 1.1k 0.8× 1.3k 1.2× 2.1k 3.0× 963 1.6× 274 0.6× 233 5.5k
Anthony Hayward United States 40 2.5k 1.8× 2.1k 1.9× 452 0.6× 450 0.8× 547 1.2× 155 5.3k
Dag Kvale Norway 33 859 0.6× 1.5k 1.4× 776 1.1× 739 1.3× 674 1.5× 101 3.7k
Gary Calandra United States 39 1.0k 0.7× 1.8k 1.7× 624 0.9× 961 1.6× 195 0.4× 104 6.2k
Roberto F. Speck Switzerland 32 874 0.6× 1.6k 1.5× 1.1k 1.6× 612 1.0× 1.5k 3.4× 119 3.5k

Countries citing papers authored by Francisco Díaz‐Mitoma

Since Specialization
Citations

This map shows the geographic impact of Francisco Díaz‐Mitoma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Díaz‐Mitoma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Díaz‐Mitoma more than expected).

Fields of papers citing papers by Francisco Díaz‐Mitoma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisco Díaz‐Mitoma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Díaz‐Mitoma. The network helps show where Francisco Díaz‐Mitoma may publish in the future.

Co-authorship network of co-authors of Francisco Díaz‐Mitoma

This figure shows the co-authorship network connecting the top 25 collaborators of Francisco Díaz‐Mitoma. A scholar is included among the top collaborators of Francisco Díaz‐Mitoma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco Díaz‐Mitoma. Francisco Díaz‐Mitoma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Merrell, Ryan, Patrick Y. Wen, Deborah Forst, et al.. (2024). Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas.. Journal of Clinical Oncology. 42(16_suppl). TPS2100–TPS2100. 2 indexed citations
3.
Vesikari, Timo, Joanne M. Langley, Johanna N. Spaans, et al.. (2023). The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine. Vaccine. 41(24). 3584–3588. 9 indexed citations
4.
Vesikari, Timo, et al.. (2023). PreHevbrio: the first approved 3-antigen hepatitis B vaccine. Expert Review of Vaccines. 22(1). 1041–1054. 9 indexed citations
5.
Langley, Joanne M., Soren Gantt, Scott A. Halperin, et al.. (2023). An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study. Vaccine. 42(3). 713–722. 11 indexed citations
6.
Iwamoto, Fábio M., Neel I. Nissen, David A. Reardon, et al.. (2023). CTIM-27. PERIPHERAL BIOMARKER ANALYSIS OF T CELL-MEDIATED COLLAGEN REMODELING CORRELATES WITH TUMOR RESPONSES IN A PHASE IIA TRIAL OF VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology. 25(Supplement_5). v68–v68. 2 indexed citations
7.
Murad, Yanal, et al.. (2015). Impact of polymerase chain reaction testing on Clostridium difficile infection rates in an acute health care facility. American Journal of Infection Control. 43(4). 383–386. 13 indexed citations
8.
9.
Tapiéro, Bruce, Scott A. Halperin, William Meekison, et al.. (2012). Safety and Immunogenicity of a Hexavalent Vaccine Administered at 2, 4 and 6 Months of Age With or Without a Heptavalent Pneumococcal Conjugate Vaccine. The Pediatric Infectious Disease Journal. 32(1). 54–61. 14 indexed citations
10.
Ghorbani, Masoud, Fengfu Li, Jessie A. Blake, et al.. (2010). Controlled Release of Acyclovir Through Bioengineered Corneal Implantswith Silica Nanoparticle Carriers. 3(1). 11 indexed citations
11.
Kang, Kyung Hee, Yasuhiro Yamamura, Maria P. Carlos, et al.. (2010). Synthetic Antigens Representing the Antigenic Variation of Human Hepatitis C Virus. Viral Immunology. 23(5). 497–508. 1 indexed citations
12.
Weltzin, Richard, et al.. (2009). Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin–streptavidin conjugated antibodies. Journal of Virological Methods. 163(2). 459–464. 7 indexed citations
13.
Díaz‐Mitoma, Francisco. (2008). Safety and Immunogenicity of a Hexavalent DTaP-IPV-Hib-HepB Vaccine Administered at 2, 4, 6, and 12-14 Months. 46th Annual Meeting. 1 indexed citations
14.
Kaita, K., Eric M. Yoshida, Derek Kunimoto, et al.. (2007). [127] Phil PROOF OF CONCEPT STUDY OF CELGOSIVIR IN COMBINATION WITH PEGINTERFERON o-2b AND RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE-1 NON-RESPONDER PATIENTS. Journal of Hepatology. 46. S56–S57. 19 indexed citations
15.
Wald, Anna, Stacy Selke, Terri Warren, et al.. (2006). Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding. Sexually Transmitted Diseases. 33(9). 529–533. 49 indexed citations
16.
Ghorbani, Masoud, Théo Nass, Ali Azizi, et al.. (2005). Comparison of Antibody- and Cell-Mediated Immune Responses After Intramuscular Hepatitis C Immunizations of BALB/c Mice. Viral Immunology. 18(4). 637–648. 10 indexed citations
17.
Gee, Katrina, Wilfred Lim, W. F. Mader, et al.. (2002). Differential Regulation of CD44 Expression by Lipopolysaccharide (LPS) and TNF-α in Human Monocytic Cells: Distinct Involvement of c-Jun N-Terminal Kinase in LPS-Induced CD44 Expression. The Journal of Immunology. 169(10). 5660–5672. 60 indexed citations
18.
19.
Doranz, Benjamin J., L G Filion, Francisco Díaz‐Mitoma, et al.. (2001). Safe Use of the CXCR4 Inhibitor ALX40-4C in Humans. AIDS Research and Human Retroviruses. 17(6). 475–486. 89 indexed citations
20.
Angel, Jonathan B., Ashok Kumar, L G Filion, et al.. (1998). Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir. The Journal of Infectious Diseases. 177(4). 898–904. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lígia A. Pinto Breakdown of academic impact, for papers by Mutsunori Shirai Breakdown of academic impact, for papers by Jian Yan Breakdown of academic impact, for papers by Alan Heath Breakdown of academic impact, for papers by Alistair J. Ramsay Breakdown of academic impact, for papers by Didier Hober Breakdown of academic impact, for papers by Anthony Hayward Breakdown of academic impact, for papers by Dag Kvale Breakdown of academic impact, for papers by Gary Calandra Breakdown of academic impact, for papers by Roberto F. Speck
Rankless by CCL
2026